79. Breast. 2018 Aug;40:53. doi: 10.1016/j.breast.2018.04.007.Erratum to "First-line ribociclib plus letrozole for postmenopausal women withHR+, HER2- ABC: MONALEESA-2 safety results" [Breast 36 (Suppl. 1) (November 2017)S44-S45].Janni W(1), Chan A(2), Nusch A(3), Alba E(4), Bachelot T(5), Gil-Gil M(6), KattanJ(7), Bourgeois H(8), El Karak F(9), Sutradhar S(10), Miller M(10), ChandiwanaD(10), Conte P(11).Author information: (1)Universitätsklinikum Ulm, Department of Oncology, Ulm, Germany. Electronicaddress: Wolfgang.Janni@uniklinik-ulm.de.(2)Curtin University, Breast Cancer Research Centre WA, Perth, Australia.(3)Onkologische Praxis, Oncology, Velbert, Germany.(4)Hospital Universitario Virgen de la Victoria, Oncology, Málaga, Spain.(5)Centre Léon Bérard, Oncology, Lyon, France.(6)L'Hospitalet de Llobregat, Institut Català d'Oncologia, Barcelona, Spain.(7)Hôtel Dieu de France Hospital, Oncology, Beirut, Lebanon.(8)Centre Jean Bernard, Oncology, Le Mans, France.(9)Bellevue Medical Center, Oncology, Mansourieh, Lebanon.(10)Novartis Pharmaceuticals Corporation, Oncology, East Hanover, NJ, USA.(11)University of Padua, Istituto Oncologico Veneto, IRCCS, Padua, Italy.DOI: 10.1016/j.breast.2018.04.007 PMID: 30005916 